Genesis Therapeutics raises a budget of $52 million for its upcoming AI-focused drug discovery project. Previously, this company competed in the Startup Battlefield at Disrupt back in 2019.
Genesis Therapeutics' performance amazed the judges, revealing that it has potential. According to Techcrunch's latest report, Evan Feinberg, the founder of Genesis Therapeutics, entered the field when his inherited illness made traditional lab work.
"I think initially the attempts were too kind of cut and paste deep learning techniques, and represent molecules a lot like images, and classify them - as you'd say, this is a cat picture or this is not a cat picture," he said via Techcrunch.
He added that the company presents the molecules more naturally, compared to other therapeutic firms. Feinberg explained that they are also representing them with multiple contact types between atoms, more complex features, and spatial distances.
This is just one example of how Genesis Therapeutics really makes efforts in its AI-driven drug discovery mission.
Genesis Therapeutics and Genentech collab
To enhance its project, the giant therapeutic firm partnered with Genentech, a member of the Roche Group. Business Wire reported that the collaboration will improve the company's graph machine learning and drug discovery expertise to identify innovative drug candidates for therapeutic targets in multiple disease areas.
"This partnership with Genentech enables us to leverage our AI technology platform with Genentech's unmatched capabilities in molecular innovation and structural biology," said Feinberg via Business Wire.
Genesis Therapeutics' works
Genesis Therapeutics, a biotechnology company, has been inventing and deploying breakthrough AI techniques. These methods are used to develop and discover drugs, both internally. Its groundbreaking deep learning technology is a unique one. As of the moment, the company is still looking to enhance its service. It was also able to augment its technical expertise with accomplished biotech veterans.
For more news updates about other bio-technologies, always keep your tabs open here at TechTimes.
This article is owned by TechTimes.
Written by: Giuliano de Leon.
